SKF 81297

SKF 81297 is a 1-phenyl-3-benzazepine, built at SmithKline and French around 1980 while the group was trying to separate central dopaminergic activity from renal ^[1]. It is the 6-chloro analogue of SKF 38393, and that single chlorine is what turns a partial agonist into a full one. It has never been a drug candidate. Its entire reason for existing is as a research reagent, and most of what is written about it online describes experiments in rats.

There is no human safety data for SKF 81297. It has never been given to a human, so there is no tolerability record, no adverse event profile and no interaction data. That is the complete and honest answer, and it should not be read as reassurance.

The concrete hazard in animals is seizures. At 2.5 and 5 mg/kg in mice, SKF 81297 induced behavioural seizures with epileptiform discharges in the dentate gyrus, blocked by SCH 23390, which confirms the effect runs through D1 ^[15]. In rat prefrontal slices, 1 micromolar lowered the threshold for epileptiform discharge to 83 percent of control and spread activity across the cortex ^[16]. This is replicated and mechanistically explained rather than incidental.

It also produces dyskinesia. In 6-OHDA-lesioned rats it is used as the inducer of abnormal involuntary movements rather than as a treatment for them ^[17], and in squirrel monkeys full D1 agonists disrupt motor behaviour more than partial ones do ^[14].

Cardiovascular effects are unknown. The chemical series was designed specifically to separate central from renal and vascular dopaminergic activity ^[1], but no cardiovascular characterisation of SKF 81297 itself was found. Unknown is not the same as safe. In chemodenervated goats it had no effect on phrenic nerve activity ^[24].

The compound comes out of a SmithKline and French medicinal chemistry programme published in 1980, which walked a series of substituted 3-benzazepines looking for one that separated central dopamine agonism from the renal vasodilator activity the parent series carried ^[1]. SKF 81297 was the 6-chloro member, and the chlorine gave full efficacy at adenylyl cyclase where the unchlorinated SKF 38393 gave partial. It was never developed further as a medicine. Instead it settled into the role it still holds four decades later: the standard full D1-like agonist in the pharmacologist's cupboard, the compound a paper reaches for when it needs D1 switched on properly.

Outside the laboratory, SKF 81297 has picked up a reputation it has not earned, mostly through a chain of secondhand claims about dopamine D1 signalling and muscle. Those claims are traceable, and they do not survive being traced ^[20][21]. Within the literature its reputation is entirely different and quite specific: it is the reference agonist, the positive control, and one of the cleanest demonstrations anywhere of an inverted-U dose response in cognition ^[7][9].